KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Receivables (2018 - 2025)

Castle Biosciences' Change in Receivables history spans 7 years, with the latest figure at -$6.3 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 915.6% year-over-year to -$6.3 million; the TTM value through Dec 2025 reached -$6.9 million, down 154.39%, while the annual FY2025 figure was -$6.9 million, 154.39% down from the prior year.
  • Change in Receivables for Q4 2025 was -$6.3 million at Castle Biosciences, down from -$1.9 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $5.8 million in Q3 2023 and bottomed at -$6.3 million in Q4 2025.
  • The 5-year median for Change in Receivables is $2.1 million (2021), against an average of $1.6 million.
  • The largest annual shift saw Change in Receivables skyrocketed 11502.0% in 2023 before it tumbled 915.6% in 2025.
  • A 5-year view of Change in Receivables shows it stood at -$1.5 million in 2021, then surged by 137.09% to $540000.0 in 2022, then soared by 113.15% to $1.2 million in 2023, then crashed by 33.19% to $769000.0 in 2024, then crashed by 915.6% to -$6.3 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Change in Receivables are -$6.3 million (Q4 2025), -$1.9 million (Q3 2025), and -$3.9 million (Q2 2025).